Clinical observation of montelukast sodium combined with cetirizine hydrochloride in treatment of children with cough variant asthma

Objective To investigate the effect of montelukast sodium combined with cetirizine hydrochloride on clinical symptoms and pulmonary function in children with cough variant asthma(CVA). Methods Totally 130 children with CVA were divided into two groups, with 65 cases in each group. The control group was treated with montelukast sodium, and the study group was treated with montelukast sodium combined with cetirizine hydrochloride. The remission time of clinical symptom, lung function index, cough symptom score and recurrence rate were compared between the two groups. Results The remission time of cough, high fever, dyspnea and time to normal result of chest X-ray in the study group were significantly shorter than those in the control group(P<0.05). After treatment, the ratio of forced expiratory volume to forced vital capacity(FEV₁/FVC)and the percentage of peak expiratory flow(PEF)to the predicted normal value in both groups were significantly higher than those before treatment, and these indexes in the study group were significantly higher than those in the control group(P<0.05). After treatment, the score of cough symptoms in both groups was significantly lower than that before treatment, and the score of cough symptoms in the study group was significantly lower than that in the control group(P<0.05). The recurrence rate of the study group was 1.54%, which was significantly lower than 12.31% of the control group(P<0.05). Conclusion Montelukast sodium combined with cetirizine hydrochloride is effective in the treatment of patients with CVA, which has the advantages of rapid effect, good efficacy and low recurrence rate, and it can significantly improve the lung function of children.